PROCESS FOR THE PURIFICATION OF GABAPENTIN

METHODE DE PURIFICATION DE LA GABAPENTINE

English Abstract

A process for the preparation of gabapentin which comprises the passage of a
gabapentin inorganic salt through a strong cationic ionic exchange resin, the
elution of gabapentin fixed on the column, the concentration of the resultant
solution and the cristallization from organic solvent, characterized in that
the elution of gabapentin fixed on the column is carried out by using an
ammonia and alkaline hydroxide aqueous solution, is described.

French Abstract

L'invention concerne une méthode de préparation de la gabapentine, qui consiste à: faire passer un sel inorganique de la gabapentine à travers une forte résine d'échange cationique ionique; éluer la gabapentine fixée sur la colonne; concentrer la solution résultante et effectuer une cristallisation à partir d'un solvant organique. La méthode se caractérise en ce que l'élution de la gabapentine fixée sur la colonne est accomplie avec une solution aqueuse d'ammoniac et d'hydroxide alcalin.

Claims

-5-
WE CLAIM
1. A process for the preparation of gabapentin which comprises the passage of
a gabapentin
inorganic salt through a column of strong cationic ionic exchange resin,
effecting elution of
gabapentin fixed on the column, concentrating the resultant solution and
crystallizing gabapentin
from organic solvent, wherein in that the elution of gabapentin fixed on the
column is carried out by
using an ammonia and alkali metal hydroxide aqueous solution.
2. A process according to claim 1 wherein the alkali metal hydroxide is NaOH.
3. A process according to claim 2 wherein the ammonia and NaOH aqueous
solution is
obtained by mixing an ammonia aqueous solution at 3-4 wt% with a sodium
hydroxide aqueous
solution at 7-8 wt%.
4. A process according to claim 1 wherein the gabapentin sodium salt that is
present in the
eluate is neutralized with an aqueous solution of HC1.
5. A process according to claim 1 which comprises fixing gabapentin on a
strong cationic resin,
washing with water, eluting the resin with an ammonia and sodium hydroxide
aqueous solution and
washing the resin with demineralised water, collecting the fractions
containing gabapentin,
concentrating the solution until about 50 vol%, neutralizing by HC1 the
present gabapentin sodium
salt, further concentrating till a thick residue, crystallizing gabapentin
from alcoholic solvents.
6. A process according to claim 3 wherein said ammonia and NaOH solution
comprises
sodium hydroxide in an amount up to a molar amount of said cationic ionic
exchange resin.

Description

CA 02528315 2005-12-06
WO 2004/113269 PCT/EP2004/006513
"PROCESS FOR THE PURIFICATION OF GABAPENTIN"
The present invention relates to a process for the preparation of gabapentin.
Gabapentin (The Merck Index XII Ed., page 733, No. 4343) is a known drug
endowed with
anti-epilectic activity described for the first time by Warner Lambert Co. in
the US patent
4,024,175.
In the literature several processes for the preparation of gabapentin are
reported (see for
example the US patents 4,024,175, 5,068,413 and 5,091,567).
Substantially, all these methods foresee a final step of purification by
column
chromatography of an aqueous solution of a gabapentin salt, generally
hydrochloride,
through a weak basic ionic exchange resin.
In the patent application PCT No. WO 02/34709 in the name of the same
Applicant, a
process of purification that foresees the chromatography of an aqueous
solution of
gabapentin hydrochloride through strong cationic ionic exchange resins is
described.
The process described in the above cited PCT patent application is very
efficient and it
allows to obtain, after concentration of the eluate and crystallization, a
high pure product,
almost completely free from the corresponding lactam which is a substance
endowed with a
certain toxicity (Von A. Enders et al., Arzneimittel Forschung, 10, (1960),
243-250).
During the chromatographic phase on cationic resin, gabapentin is fixed to the
resin allowing
the other substances to percolate, in particular organic impurities coming
from the synthetic
process.
Gabapentin is then eluted with an ammonia aqueous solution with a
concentration around 3-
4% and then with water.
The fractions containing gabapentin are collected and concentrated under
vacuum till
obtaining a solid residue from which gabapentin is isolated by crystallization
from organic
solvents, preferably alcoholic solvents.
The above described process itself appears [to be] optimum with regard to the
purification of
gabapentin.
Nevertheless, said process needs a high amount of ammonia solution (about 4500
liters at
3% for 350 Kg of gabapentin). The ammonia solution must then be drained by a
biological
CONFIRMATION COPY

CA 02528315 2010-11-10
-2-
draining system and this results both in an increase in costs and in a
prolonged utilization of the
draining system itself.
SUMMARY OF THE INVENTION
We have now found a variation to the process described in the patent
application PCT
No. WO 02/34709 which allows to considerably reduce the amount of the used
ammonia
solution obtaining at the same time an equally pure product and with
substantially the same
yields.
Said variation consists in eluting gabapentin fixed on the strong cationic
resin with an ammonia
and alkaline hydroxide aqueous solution.
Therefore, object of the present invention is a process for the preparation of
gabapentin which
comprises the passage of a gabapentin inorganic salt through a strong cationic
ionic exchange
resin, the elution of gabapentin fixed on the column, the concentration of the
resultant solution
and the crystallization from organic solvent, characterized by the fact that
the elution of
gabapentin fixed on the column is carried out by using an ammonia and alkaline
hydroxide
aqueous solution.
Accordingly, in one aspect, the present invention provides a process for the
preparation of
gabapentin which comprises the passage of a gabapentin inorganic salt through
a column of
strong cationic ionic exchange resin, effecting elution of gabapentin fixed on
the column,
concentrating the resultant solution and crystallizing gabapentin from organic
solvent, wherein
in that the elution of gabapentin fixed on the column is carried out by using
an ammonia and
alkali metal hydroxide aqueous solution.
Preferably, for economic reasons purely, the alkaline hydroxide is sodium
hydroxide.
Not limitative examples of strong cationic resins useful in the process of the
invention are
IRA120*, DIAION* SKIS and IMAC* HP1110.
The amount of alkaline hydroxide must not exceed the molar amount of cationic
resin used in
order to minimize the amount of alkaline hydroxide which elutes with
gabapentin forming an
alkaline salt of gabapentin.
*Trade-Mark

CA 02528315 2010-11-10
-2a-
Preferably, the concentration of NH3 in the elution solutions is around 3-4%
by weight and the
concentration of NaOH around 7% by weight. The ratio between NH3 and NaOH is
preferably
from 1: 1 to 1: 2.
At the end of elution the column is washed with demineralised water.
Practically, the method object of the invention allows to substitute a
relevant amount (about 60-
70%) of ammonia with sodium hydroxide and this results in a significant
reduction of draining
time and costs of the ammonia solution.
As further collateral advantage, the eluate volume is reduced of about 20 %
with further
reduction of costs and time.
Thus, for example, if 4500 1 of an aqueous solution of NH3 at 3 % every 350 Kg
of

CA 02528315 2005-12-06
WO 2004/113269 PCT/EP2004/006513
-3-
gabapentin by the method described in the patent application PCT No. WO
02/34709 were
necessary, 4100 1 of an aqueous solution of NH3 at 3% (1400 1) and a solution
of NaOH at
7% (2700 1) for the same amount of gabapentin by the method object of the
present invention
are sufficient.
The eluate also contains a small amount of alkaline hydroxide in the form of
gabapentin salt,
for example sodium salt, which may possess a destabilizing effect on
gabapentin.
Nevertheless, the elimination of the sodium salt can be realized by adding a
small amount of
mineral acid to the solution, preferably HC1.
HC1 (a diluted aqueous solution) can be directly added in the eluate or after
having
concentrated it at about 50% by distillation i.e after having substantially
removed the
ammonia.
The subsequent crystallization according to known techniques removes a great
part of the
chlorides added, giving gabapentin containing chlorides between 30 and 70 ppm
i.e. in line
with pharmacopoeia requirements (less than 100 ppm).
In a practical embodiment the process of the invention comprises fixing
gabapentin on a
strong cationic resin, washing with water in order to remove the inorganic
acid, eluting the
resin with an ammonia and sodium hydroxide aqueous solution and washing the
resin with
demineralised water, collecting the fractions containing gabapentin,
concentrating the
solution till about 50%, neutralizing the present sodium salt of gabapentin
with HC1, further
concentrating till obtaining a thick residue, crystallizing gabapentin from
alcoholic solvents.
For better illustrating the present invention the following examples are now
given.
Example 1
In a glass column (diameter 45 mm, height 450 mm) endowed with porous septum,
500 ml
of suitably activated and regenerated resin Diaion SK1B were charged.
A solution of gabapentin hydrochloride (652 g of solution at 14.48% equal to
94.4 g of
gabapentin) was eluted through the column.
The column was then washed eluting with demineralised water about 1500 g till
pH 7.
Then, a mixture (720 g) of an ammonia solution at 3% (240 g) and a solution of
NaOH at 7%
(480 g) was eluted through the column.

CA 02528315 2005-12-06
WO 2004/113269 PCT/EP2004/006513
-4-
At the end the column was eluted with demineralised water till pH 7 (about
1500 g).
The fractions of eluate containing gabapentin were collected obtaining a
solution (2171 g)
containing gabapentin (4.25%, 92.3 g).
To the solution, 23.4 g of HCl solution at 3.99% (equal to 0.934 g of HCl) was
added.
The solution was then concentrated under vacuum at a temperature below 40 C
obtaining a
crude (91.2 g) containing gabapentin at 97.6%.
In a 500 ml reactor under nitrogen crude gabapentin (70 g), demineralised
water (34.7 g) and
methanol (43.7 g) were charged.
The suspension was heated at 50 C for 30 minutes and then isopropyl alcohol
(180.5 g) was
added dropwise in 30 minutes.
The mixture was kept at 50 C for further 30 minutes and then it was cooled at
25 C in 2
hours and at -5 C in a further hour, keeping this temperature for further 2
hours.
The solid was filtered and washed on the filter with isopropyl alcohol cooled
at -5 C.
After drying in oven at 45 C, gabapentin (64 g) was obtained with purity
higher than 99%,
lactam under 0.01% and 69 ppm of chlorides (expressed as CI-).